[{"NetIncomeLoss_1_Q2_USD":-193399000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"InterestIncomeOther_2_Q2_USD":406000.0,"InterestIncomeOther_1_Q2_USD":180000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":15405000.0,"BusinessCombinationContingentConsiderationLiability_0_Q2_USD":48465000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-64000.0,"IncreaseDecreaseInCommodityContractAssetsAndLiabilities_2_Q2_USD":-3462000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":132744000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-207553000.0,"Depreciation_2_Q2_USD":1879000.0,"PaymentsToAcquireInvestments_2_Q2_USD":646239000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":80000.0,"AssetsCurrent_0_Q2_USD":681276000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":9411587.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":9411587.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":1123000.0,"ResearchAndDevelopmentInProcess_2_Q2_USD":123000000.0,"ResearchAndDevelopmentInProcess_1_Q2_USD":123000000.0,"CommonStockSharesIssued_0_Q2_shares":92552645.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":411151000.0,"Assets_0_Q2_USD":714401000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":91939439.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":91188160.0,"GeneralAndAdministrativeExpense_1_Q2_USD":14422000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":27156000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":8261000.0,"LettersOfCreditOutstandingAmount_0_Q2_USD":1700000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":402000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":181000.0,"AccountsReceivableNetCurrent_0_Q2_USD":279000.0,"Revenues_2_Q2_USD":1796000.0,"Revenues_1_Q2_USD":844000.0,"ContractWithCustomerAssetNet_0_Q2_USD":4193000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_Q2_USD":75769000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q2_USD":45147000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-128000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":3176000.0,"FairValueOfAssetsAcquired_2_Q2_USD":662000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_2_Q2_USD":-128000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_1_Q2_USD":-76000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-235710000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-193475000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-867000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":260069000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":22022000.0,"Liabilities_0_Q2_USD":95872000.0,"Investments_0_Q2_USD":411151000.0,"RestrictedCash_0_Q2_USD":2578000.0,"IncreaseDecreaseInPrepaidExpense_2_Q2_USD":-4964000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-76000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":21688000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-639811000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-185877000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":-74801000.0,"CommonStockSharesOutstanding_0_Q2_shares":92552645.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0_Q2_shares":10653994.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":16000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":16147000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":18500000.0,"LiabilitiesCurrent_0_Q2_USD":25385000.0,"AccountsPayableCurrent_0_Q2_USD":7871000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":262647000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":5584000.0,"AreaOfLand_0_Q2_sqft":46631.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":-22000.0,"StockIssued1_2_Q2_USD":61948000.0,"AdditionalPaidInCapital_0_Q2_USD":1258312000.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":2300000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":1077000.0,"ProceedsFromSaleAndMaturityOfOtherInvestments_2_Q2_USD":464673000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":6559000.0,"NetIncomeLoss_2_Q2_USD":-235582000.0,"OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_1_Q2_USD":-76000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":-701000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":411215000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":855000.0,"VariableInterestEntityInitialConsolidationGainOrLoss_2_Q2_USD":-11855000.0,"VariableInterestEntityInitialConsolidationGainOrLoss_1_Q2_USD":-11855000.0,"StockIssuedDuringPeriodValueAcquisitions_1_Q2_USD":61948000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":3176000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"PaymentsToAcquireBusinessesNetOfCashAcquired_2_Q2_USD":25132000.0,"CommonStockSharesAuthorized_0_Q2_shares":150000000.0,"CommonStockValueOutstanding_0_Q2_USD":92000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":1796000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":844000.0,"ShareBasedCompensation_2_Q2_USD":25818000.0,"OperatingIncomeLoss_2_Q2_USD":-235984000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":414000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":714401000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":25818000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":16147000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1695000.0,"OperatingExpenses_2_Q2_USD":237780000.0,"OperatingExpenses_1_Q2_USD":194424000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-2.58,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-2.1,"StockholdersEquity_0_Q2_USD":618529000.0,"OperatingIncomeLoss_1_Q2_USD":-193580000.0,"LiabilitiesAssumed1_2_Q2_USD":2330000.0,"Ticker":"RLAY","CIK":"1812364","name":"RELAY THERAPEUTICS, INC.","OfficialName":"Relay Therapeutics Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"3171086334.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210812"}]